Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: Cardiopulmonary Toxicity of Thoracic Radiotherapy
A clinical trial is evaluating the cardiopulmonary toxicity of thoracic radiotherapy in patients with esophageal cancer and non-small cell l…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC [Phase 2]
Phase II trial evaluates re-challenge with pembrolizumab as second- or later-line therapy in patients with advanced Non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial of ONO-4538 (nivolumab) in patients with advanced non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-21Clinical Trial Update: Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer [Phase 2]
A Phase II trial evaluating concurrent durvalumab with radiotherapy for Stage III Non-Small Cell Lung Cancer has completed and results were …
-
CLINICAL_TRIALS trial_result · 2025-03-21Clinical Trial Update: Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers [Phase 1]
Phase 1 study of the oral STAT3 inhibitor TTI-101 in patients with advanced cancers has completed, with enrollment across multiple tumor typ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-21Clinical Trial Update: Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC [Phase 1, Phase 2]
The document indicates that the Phase 1/2 clinical trial of YH25448 in EGFR mutation-positive advanced non-small cell lung cancer has comple…
-
CLINICAL_TRIALS trial_result · 2025-03-21Clinical Trial Update: A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
This update reports the completion of a multicenter clinical trial evaluating sputum DNA testing for lung cancer in China, sponsored by Crea…
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC [Phase 2]
A Phase 2 trial is evaluating neoadjuvant Firmonertinib combined with chemotherapy for resectable stage II-IIIb EGFR-mutant non-small cell l…
-
CLINICAL_TRIALS trial_result · 2025-03-21Clinical Trial Update: Abequolixron (RGX-104) and Durvalumab in Lung Cancer [Phase 1]
Phase 1 trial evaluating Abequolixron (RGX-104) in combination with Durvalumab for non-small cell lung cancer was terminated.
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) [Phase 1, Phase 2]
A Phase 1b/2 dose-escalation trial of entinostat with pembrolizumab in non-small cell lung cancer, with expansion cohorts in melanoma and co…
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
A clinical trial update indicates recruitment for a study using long-read sequencing to characterize EGFR alterations in EGFR-positive non-s…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. [Phase 2]
A Phase 2 study of MCLA-129 for advanced non-small cell lung cancer with AGA and MET amplification is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma [Phase 1]
Phase 1 study of Nous-PEV for melanoma and non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Biomarkers for Risk Stratification in Lung Cancer
Ongoing clinical trial update focusing on biomarkers for risk stratification in lung cancer, with recruitment for solitary pulmonary nodule …
-
FDA approval · 2025-03-19FDA Approved: TAFINLAR — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TAFINLAR (dabrafenib) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment [Phase 1, Phase 2]
The update reports on the relative bioavailability/bioequivalence of different selinexor formulations, the impact of hepatic impairment on s…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer
A completed clinical trial evaluating risk factors for oral mucositis/stomatitis and ocular surface events in patients with advanced/metasta…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer [Phase 2]
An open-label, single-arm Phase 2 trial evaluating Stapokibart in combination with tislelizumab for non-small cell lung cancer, with status …
-
CLINICAL_TRIALS withdrawal · 2025-03-19Clinical Trial Update: A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer's post-marketing surveillance study of Zirabev to assess safety and effectiveness in domestic cancer patients has been withdrawn.
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC [Phase 2]
A Phase II clinical trial evaluating SHR-1826 injections in patients with non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
Clinical trial status update indicates an ongoing first-line study of sintilimab combined with platinum-containing double-agent chemotherapy…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Multimodal Prehabilitation in Patients with Lung Cancer Undergoing Neoadjuvant Therapy [NA]
This clinical trial update describes a study evaluating multimodal prehabilitation for patients with non-small cell lung cancer undergoing n…
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 clinical trial update comparing relatlimab plus nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatme…
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 study of BMS-986442 with nivolumab, with or without chemotherapy, in solid tumors and non-small cell lung cancer has been terminat…
-
CLINICAL_TRIALS research · 2025-03-18Clinical Trial Update: Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer [Phase 2]
A Phase 2 clinical trial update comparing pembrolizumab given every 12 weeks versus every 3 weeks in patients with non-small cell lung cance…